Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2005 2
2006 3
2007 2
2009 2
2010 4
2011 4
2012 4
2013 4
2014 6
2015 3
2016 5
2017 5
2018 3
2019 4
2020 5
2021 6
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

51 results
Results by year
Filters applied: . Clear all
Page 1
PD-L1 on mast cells suppresses effector CD8+ T-cell activation in the skin in murine contact hypersensitivity.
Hirano T, Honda T, Kanameishi S, Honda Y, Egawa G, Kitoh A, Nakajima S, Otsuka A, Nomura T, Dainichi T, Yaguchi T, Inozume T, Kataoka TR, Tamada K, Kabashima K. Hirano T, et al. Among authors: inozume t. J Allergy Clin Immunol. 2021 Aug;148(2):563-573.e7. doi: 10.1016/j.jaci.2020.12.654. Epub 2021 Feb 10. J Allergy Clin Immunol. 2021. PMID: 33581199
[Recent clinical trials of tumor immunotherapy].
Inozume T. Inozume T. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(3):134-8. doi: 10.2177/jsci.36.134. Nihon Rinsho Meneki Gakkai Kaishi. 2013. PMID: 23812070 Free article. Review. Japanese.
Mutant KRAS Promotes NKG2D+ T Cell Infiltration and CD155 Dependent Immune Evasion.
Nishi K, Ishikura S, Umebayashi M, Morisaki T, Inozume T, Kinugasa T, Aoki M, Nimura S, Swain A, Yoshida Y, Hasegawa S, Nabeshima K, Sakata T, Shirasawa S, Tsunoda T. Nishi K, et al. Among authors: inozume t. Anticancer Res. 2020 Aug;40(8):4663-4674. doi: 10.21873/anticanres.14465. Anticancer Res. 2020. PMID: 32727790
Immunotherapy with 4-1BBL-Expressing iPS Cell-Derived Myeloid Lines Amplifies Antigen-Specific T Cell Infiltration in Advanced Melanoma.
Kuriyama H, Fukushima S, Kimura T, Kanemaru H, Miyashita A, Okada E, Kubo Y, Nakahara S, Tokuzumi A, Nishimura Y, Kajihara I, Makino K, Aoi J, Masuguchi S, Tsukamoto H, Inozume T, Zhang R, Nakatsura T, Uemura Y, Senju S, Ihn H. Kuriyama H, et al. Among authors: inozume t. Int J Mol Sci. 2021 Feb 16;22(4):1958. doi: 10.3390/ijms22041958. Int J Mol Sci. 2021. PMID: 33669419 Free PMC article.
PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes.
Nagasaki J, Inozume T, Sax N, Ariyasu R, Ishikawa M, Yamashita K, Kawazu M, Ueno T, Irie T, Tanji E, Morinaga T, Honobe A, Ohnuma T, Yoshino M, Iwata T, Kawase K, Sasaki K, Hanazawa T, Kochin V, Kawamura T, Matsue H, Hino M, Mano H, Suzuki Y, Nishikawa H, Togashi Y. Nagasaki J, et al. Among authors: inozume t. Cell Rep. 2022 Feb 1;38(5):110331. doi: 10.1016/j.celrep.2022.110331. Cell Rep. 2022. PMID: 35108529 Free article.
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y, Namikawa K, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Fujimoto N, Kuwatsuka Y, Onishi M, Kaneko T, Onuma T, Umeda Y, Ogata D, Takahashi A, Otsuka M, Teramoto Y, Yamazaki N. Nakamura Y, et al. Among authors: inozume t. ESMO Open. 2021 Dec;6(6):100325. doi: 10.1016/j.esmoop.2021.100325. Epub 2021 Nov 25. ESMO Open. 2021. PMID: 34839104 Free PMC article.
51 results